Kinase-Kinase Interaction and Modulation of Tau Phosphorylation

International Review of Cell and Molecular Biology

Volumn 300, Issue , 2013, Pages 121-160

  Hashiguchi, Mitsuko ^a   Hashiguchi, Toshio ^b  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Kuretake School of Integrative Medicine   (Japan)

Author keywords

Complementary kinase action; Multisite phosphorylation; Protein protein interaction; Tau; Tau phosphorylation protein complex (TPPC); Topographical modulation

Indexed keywords

ALPHA SYNUCLEIN; CHAPERONE; PHOSPHATASE; PHOSPHOTRANSFERASE; SCAFFOLD PROTEIN; TAU PROTEIN;

ARTICLE; CATALYSIS; HUMAN; MICROTUBULE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

EID: 84871710082     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-405210-9.00004-7     Document Type: Chapter

References (150)

1. Abraha A., Ghoshal N., Gamblin T.C., Cryns V., Berry R.W., Kuret J., Binder L.I. C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J. Cell Sci. 2000, 113(Pt 21):3737-3745.
2. Agarwal-Mawal A., Paudel H.K. Neuronal Cdc2-like protein kinase (Cdk5/p25) is associated with protein phosphatase 1 and phosphorylates inhibitor-2. J. Biol. Chem. 2001, 276:23712-23718.
3. Agarwal-Mawal A., Qureshi H.Y., Cafferty P.W., Yuan Z., Han D., Lin R., Paudel H.K. 14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex. J. Biol. Chem. 2003, 278:12722-12728.
4. Aitken A. 14-3-3 proteins: a historic overview. Semin. Cancer Biol. 2006, 16:162-172.
5. Alonso A., Zaidi T., Novak M., Grundke-Iqbal I., Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. USA 2001, 98:6923-6928.
6. Alonso A.D., Di Clerico J., Li B., Corbo C.P., Alaniz M.E., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J. Biol. Chem. 2010, 285:30851-30860.
7. Angelo M., Plattner F., Giese K.P. Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J. Neurochem. 2006, 99:353-370.
8. Angelo M., Plattner F., Irvine E.E., Giese K.P. Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression. Eur. J. Neurosci. 2003, 18:423-431.
9. Aronov S., Aranda G., Behar L., Ginzburg I. Axonal tau mRNA localization coincides with tau protein in living neuronal cells and depends on axonal targeting signal. J. Neurosci. 2001, 21:6577-6587.
10. Augustinack J.C., Schneider A., Mandelkow E., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002, 103:26-35.
11. Basurto-Islas G., Luna-Muñoz J., Guillozet-Bongaarts A.L., Binder L.I., Mena R., García-Sierra F. Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2008, 67:470-483.
12. Bennecib M., Gong C.X., Grundke-Iqbal I., Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett. 2000, 485:87-93.
13. Bhat K.M., Setaluri V. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010, 9:790-803.
14. Biernat J., Gustke N., Drewes G., Mandelkow E.M., Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11:153-163.
15. Billingsley M.L., Kincaid R.L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem. J. 1997, 323(Pt 3):577-591.
16. Braak H., Thal D.R., Ghebremedhin E., Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011, 70:960-969.
17. Buttrick G.J., Wakefield J.G. PI3-K and GSK-3: Akt-ing together with microtubules. Cell Cycle 2008, 7:2621-2625.
18. Cheung Z.H., Ip N.Y. The roles of cyclin-dependent kinase 5 in dendrite and synapse development. Biotechnol. J. 2007, 2:949-957.
19. Chun J., Kwon T., Lee E.J., Kim C.H., Han Y.S., Hong S.K., Hyun S., Kang S.S. 14-3-3 Protein mediates phosphorylation of microtubule-associated protein tau by serum- and glucocorticoid-induced protein kinase 1. Mol. Cells 2004, 18:360-368.
20. Clodfelder-Miller B., Sarno P.D., Zmijewska A.A., Song L., Jope R.S. Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J. Biol. Chem. 2005, 280:39723-39731.
21. Cole A., Frame S., Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem. J. 2004, 377:249-255.
22. Cripps D., Thomas S.N., Jeng Y., Yang F., Davies P., Yang A.J. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J. Biol. Chem. 2006, 281:10825-10838.
23. Cruz J.C., Tsai L.H. A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr. Opin. Neurobiol. 2004, 14:390-394.
24. Culvenor J.G., McLean C.A., Cutt S., Campbell B.C., Maher F., Jäkälä P., Hartmann T., Beyreuther K., Masters C.L., Li Q.X. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am. J. Pathol. 1999, 155:1173-1181.
25. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998, 273:9443-9449.
26. Dhavan R., Tsai L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2001, 2:749-759.
27. Dickson D.W., Ksiezak-Reding H., Liu W.K., Davies P., Crowe A., Yen S.H. Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site. Acta Neuropathol. 1992, 84:596-605.
28. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116:1175-1186.
29. Dolan P.J., Johnson G.V. A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J. Biol. Chem. 2010, 285:21978-21987.
30. Dou F., Netzer W.J., Tanemura K., Li F., Hartl F.U., Takashima A., Gouras G.K., Greengard P., Xu H. Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. USA 2003, 100:721-726.
31. Drewes G., Mandelkow E.M., Baumann K., Goris J., Merlevede W., Mandelkow E. Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A. FEBS Lett. 1993, 336:425-432.
32. Fiol C.J., Mahrenholz A.M., Wang Y., Roeske R.W., Roach P.J. Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. 1987, 262:14042-14048.
33. Frame S., Cohen P., Biondi R.M. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 2001, 7:1321-1327.
34. Fukuchi K., Hart M., Li L. Alzheimer's disease and heparan sulfate proteoglycan. Front. Biosci. 1998, 3:d327-d337.
35. García-Sierra F., Ghoshal N., Quinn B., Berry R.W., Binder L.I. Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J. Alzheimers Dis. 2003, 5:65-77.
36. Gärtner U., Janke C., Holzer M., Vanmechelen E., Arendt T. Postmortem changes in the phosphorylation state of tau-protein in the rat brain. Neurobiol. Aging 1998, 19:535-543.
37. Ghoshal N., García-Sierra F., Wuu J., Leurgans S., Bennett D.A., Berry R.W., Binder L.I. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp. Neurol. 2002, 177:475-493.
38. Graeser R., Gannon J., Poon R.Y., Dubois T., Aitken A., Hunt T. Regulation of the CDK-related protein kinase PCTAIRE-1 and its possible role in neurite outgrowth in Neuro-2A cells. J. Cell Sci. 2002, 115:3479-3490.
39. Grant P., Pant H.C. Neurofilament protein synthesis and phosphorylation. J. Neurocytol. 2000, 29:843-872.
40. Gunawardena J. Multisite protein phosphorylation makes a good threshold but can be a poor switch. Proc. Natl. Acad. Sci. USA 2005, 102:14617-14622.
41. Guo Q. When good Cdk5 turns bad. Sci. Aging Knowledge Environ. 2006, 2006:pe5.
42. Hamdane M., Sambo A.V., Delobel P., Bégard S., Violleau A., Delacourte A., Bertrand P., Benavides J., Buée L. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J. Biol. Chem. 2003, 278:34026-34034.
43. Han D., Qureshi H.Y., Lu Y., Paudel H.K. Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. J. Biol. Chem. 2009, 284:13422-13433.
44. Hanger D.P., Byers H.L., Wray S., Leung K., Saxton M.J., Seereeram A., Reynolds C.H., Ward M.A., Anderton B.H. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 2007, 282:23645-23654.
45. Harwood A.J. Regulation of GSK-3: a cellular multiprocessor. Cell 2001, 105:821-824.
46. Hashiguchi M., Saito T., Hisanaga S., Hashiguchi T. Cleavage of CDK5 activator p35 enhances site-specific phosphorylation of human tau. Mol. Biol. Cell 2002, 13:438a. (abstract).
47. Hashiguchi M., Saito T., Hisanaga S., Hashiguchi T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J. Biol. Chem. 2002, 277:44525-44530.
48. Hashiguchi M., Sobue K., Paudel H.K. Regulation of tau protein phosphorylation by 14-3-3 protein. Mol. Biol. Cell 1999, 10:375a. (abstract).
49. Hashiguchi M., Sobue K., Paudel H.K. 14-3-3zeta is an effector of tau protein phosphorylation. J. Biol. Chem. 2000, 275:25247-25254.
50. Hashiguchi M., Sobue K., Paudel H.K., Hashiguchi T. Modulatory role of 14-3-3z on tau phosphorylation. Mol. Biol. 2000, 11:363a. (abstract).
51. Hernández F., Cuadros R., Avila J. Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. Neurosci. Lett. 2004, 357:143-146.
52. Hisanaga S., Saito T. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. Neurosignals 2003, 12:221-229.
53. Hou Z., Li Q., He L., Lim H.Y., Fu X., Cheung N.S., Qi D.X., Qi R.Z. Microtubule association of the neuronal p35 activator of Cdk5. J. Biol. Chem. 2007, 282:18666-18670.
54. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J. Neural Transm. 1998, 105:415-422.
55. Illenberger S., Zheng-Fischhöfer Q., Preuss U., Stamer K., Baumann K., Trinczek B., Biernat J., Godemann R., Mandelkow E.M., Mandelkow E. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol. Biol. Cell 1998, 9:1495-1512.
56. Iqbal K., Liu F., Gong C.X., Alonso A.D.C., Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009, 118:53-69.
57. Janson J., Laedtke T., Parisi J.E., O'Brien P., Petersen R.C., Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
58. Jeganathan S., Hascher A., Chinnathambi S., Biernat J., Mandelkow E.M., Mandelkow E. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J. Biol. Chem. 2008, 283:32066-32076.
59. Jellinger K.A. Interaction between α-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal. 2011, 11:1893-1907.
60. Jensen P.H., Hager H., Nielsen M.S., Hojrup P., Gliemann J., Jakes R. Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 1999, 274:25481-25489.
61. Jessberger S., Gage F.H., Eisch A.J., Lagace D.C. Making a neuron: Cdk5 in embryonic and adult neurogenesis. Trends Neurosci. 2009, 32:575-582.
62. Jinwal U.K., Koren J., O'Leary J.C., Jones J.R., Abisambra J.F., Dickey C.A. Hsp70 ATPase modulators as therapeutics for Alzheimer's and other neurodegenerative diseases. Mol. Cell. Pharmacol. 2010, 2:43-46.
63. Kawakami F., Suzuki M., Shimada N., Kagiya G., Ohta E., Tamura K., Maruyama H., Ichikawa T. Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β. FEBS J. 2011, 278:4895-4904.
64. Khurana V., Elson-Schwab I., Fulga T.A., Sharp K.A., Loewen C.A., Mulkearns E., Tyynelä J., Scherzer C.R., Feany M.B. Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLoS Genet. 2010, 6. e1001026.
65. Ko J., Humbert S., Bronson R.T., Takahashi S., Kulkarni A.B., Li E., Tsai L.H. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J. Neurosci. 2001, 21:6758-6771.
66. Ko L.W., Rush T., Sahara N., Kersh J.S., Easson C., Deture M., Lin W.L., Connor Y.D., Yen S.C.H. Assembly of filamentous tau aggregates in human neuronal cells. J. Alzheimers Dis. 2004, 6:605-622. discussion 673-81.
67. Kobayashi H., Hashiguchi T., Ushiyama N. Postsynaptic modulation of excitatory process in sympathetic ganglia by cyclic AMP. Nature 1978, 271:268-270.
68. Koren J., Jinwal U.K., Lee D.C., Jones J.R., Shults C.L., Johnson A.G., Anderson L.J., Dickey C.A. Chaperone signalling complexes in Alzheimer's disease. J. Cell. Mol. Med. 2009, 13:619-630.
69. Kusakawa G., Saito T., Onuki R., Ishiguro K., Kishimoto T., Hisanaga S. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 2000, 275:17166-17172.
70. Layfield R., Fergusson J., Aitken A., Lowe J., Landon M., Mayer R.J. Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci. Lett. 1996, 209:57-60.
71. Lee M.S., Tsai L.H. Cdk5: one of the links between senile plaques and neurofibrillary tangles?. J. Alzheimers Dis. 2003, 5:127-137.
72. Lee S., Sato Y., Nixon R.A. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. J. Neurosci. 2011, 31:7817-7830.
73. Li T., Chalifour L.E., Paudel H.K. Phosphorylation of protein phosphatase 1 by cyclin-dependent protein kinase 5 during nerve growth factor-induced PC12 cell differentiation. J. Biol. Chem. 2007, 282:6619-6628.
74. Li T., Hawkes C., Qureshi H.Y., Kar S., Paudel H.K. Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 2006, 45:3134-3145.
75. Li T., Paudel H.K. Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry 2006, 45:3125-3133.
76. Li T., Paudel H.K. 14-3-3zeta facilitates GSK3beta-catalyzed tau phosphorylation in HEK-293 cells by a mechanism that requires phosphorylation of GSK3beta on Ser9. Neurosci. Lett. 2007, 414:203-208.
77. Liao H., Li Y., Brautigan D.L., Gundersen G.G. Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau. J. Biol. Chem. 1998, 273:21901-21908.
78. Libet B., Tosaka T. Dopamine as a synaptic transmitter and modulator in sympathetic ganglia: a different mode of synaptic action. Proc. Natl. Acad. Sci. USA 1970, 67:667-673.
79. Lin T.H., Chen Y.C., Chyan C.L., Tsay L.H., Tang T.C., Jeng H.H., Lin F.M., Huang H.B. Phosphorylation by glycogen synthase kinase of inhibitor-2 does not change its structure in free state. FEBS Lett. 2003, 554:253-256.
80. Lindwall G., Cole R.D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 1984, 259:5301-5305.
81. Liu F., Liang Z., Shi J., Yin D., El-Akkad E., Grundke-Iqbal I., Iqbal K., Gong C. PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett. 2006, 580:6269-6274.
82. Liu S.J., Zhang J.Y., Li H.L., Fang Z.Y., Wang Q., Deng H.M., Gong C.X., Grundke-Iqbal I., Iqbal K., Wang J.Z. Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J. Biol. Chem. 2004, 279:50078-50088.
83. Liu X., Bardwell L., Nie Q. A combination of multisite phosphorylation and substrate sequestration produces switchlike responses. Biophys. J. 2010, 98:1396-1407.
84. Liu Y.H., Wei W., Yin J., Liu G.P., Wang Q., Cao F.Y., Wang J.Z. Proteasome inhibition increases tau accumulation independent of phosphorylation. Neurobiol. Aging 2009, 30:1949-1961.
85. Lu Y., Li T., Qureshi H.Y., Han D., Paudel H.K. Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain. J. Biol. Chem. 2011, 286:20569-20581.
86. Luna-Muñoz J., Chávez-Macías L., García-Sierra F., Mena R., Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J. Alzheimers Dis. 2007, 12:365-375.
87. Luna-Muñoz J., Peralta-Ramirez J., Chávez-Macías L., Harrington C.R., Wischik C.M., Mena R. Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints. Acta Neuropathol. 2008, 116:507-515.
88. Maccioni R.B., Otth C., Concha I.I., Muñoz J.P. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur. J. Biochem. 2001, 268:1518-1527.
89. Mesco E.R., Timiras P.S. Tau-ubiquitin protein conjugates in a human cell line. Mech. Ageing Dev. 1991, 61:1-9.
90. Mondragón-Rodríguez S., Basurto-Islas G., Santa-Maria I., Mena R., Binder L.I., Avila J., Smith M.A., Perry G., García-Sierra F. Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int. J. Exp. Pathol. 2008, 89:81-90.
91. Nagiec E.W., Sampson K.E., Abraham I. Mutated tau binds less avidly to microtubules than wildtype tau in living cells. J. Neurosci. Res. 2001, 63:268-275.
92. Niewiadomska G., Baksalerska-Pazera M., Riedel G. Altered cellular distribution of phospho-tau proteins coincides with impaired retrograde axonal transport in neurons of aged rats. Ann. N. Y. Acad. Sci. 2005, 1048:287-295.
93. Nixon R.A., Wegiel J., Kumar A., Yu W.H., Peterhoff C., Cataldo A., Cuervo A.M. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 2005, 64:113-122.
94. Obsilová V., Silhan J., Boura E., Teisinger J., Obsil T. 14-3-3 proteins: a family of versatile molecular regulators. Physiol. Res. 2008, 57(Suppl. 3):S11-S21.
95. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., Wolozin B. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 1999, 19:5782-5791.
96. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53:1937-1942.
97. Otvos L., Feiner L., Lang E., Szendrei G.I., Goedert M., Lee V.M. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 1994, 39:669-673.
98. Patrick G.N., Zukerberg L., Nikolic M., de Monte S.L., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
99. Patterson K.R., Remmers C., Fu Y., Brooker S., Kanaan N.M., Vana L., Ward S., Reyes J.F., Philibert K., Glucksman M.J., Binder L.I. Characterization of prefibrillar tau oligomers in vitro and in Alzheimer disease. J. Biol. Chem. 2011, 286:23063-23076.
100. Paudel H.K. The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase. J. Biol. Chem. 1997, 272:1777-1785.
101. Peng P., Zhao J., Zhu Y., Asami T., Li J. A direct docking mechanism for a plant GSK3-like kinase to phosphorylate its substrates. J. Biol. Chem. 2010, 285:24646-24653.
102. Plattner F., Angelo M., Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 2006, 281:25457-25465.
103. Poppek D., Keck S., Ermak G., Jung T., Stolzing A., Ullrich O., Davies K.J.A., Grune T. Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem. J. 2006, 400:511-520.
104. Porzig R., Singer D., Hoffmann R. Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem. Biophys. Res. Commun. 2007, 358:644-649.
105. Preuss U., Döring F., Illenberger S., Mandelkow E.M. Cell cycle-dependent phosphorylation and microtubule binding of tau protein stably transfected into Chinese hamster ovary cells. Mol. Biol. Cell 1995, 6:1397-1410.
106. Rahman A., Grundke-Iqbal I., Iqbal K. Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem. Res. 2005, 30:277-287.
107. Rahman A., Grundke-Iqbal I., Iqbal K. PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau. J. Neural. Transm. 2006, 113:219-230.
108. Rankin C.A., Sun Q., Gamblin T.C. Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation. Brain Res. Mol. Brain Res. 2005, 138:84-93.
109. Rankin C.A., Sun Q., Gamblin T.C. Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Mol. Neurodegener. 2007, 2:12.
110. Sadik G., Tanaka T., Kato K., Yamamori H., Nessa B.N., Morihara T., Takeda M. Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: implications for the mechanism of tau aggregation. J. Neurochem. 2009, 108:33-43.
111. Sadik G., Tanaka T., Kato K., Yanagi K., Kudo T., Takeda M. Differential interaction and aggregation of 3-repeat and 4-repeat tau isoforms with 14-3-3[zeta] protein. Biochem. Biophys. Res. Commun. 2009, 383:37-41.
112. Schneider A., Biernat J., Bergen M.V., Mandelkow E., Mandelkow E.M. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999, 38:3549-3558.
113. Schneider A., Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 2008, 5:443-457.
114. Schrijvers E.M., Witteman J.C., Sijbrands E.J., Hofman A., Koudstaal P.J., Breteler M.M. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 2010, 75:1982-1987.
115. Schubert M., Brazil D.P., Burks D.J., Kushner J.A., Ye J., Flint C.L., Farhang-Fallah J., Dikkes P., Warot X.M., Rio C., Corfas G., White M.F. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. 2003, 23:7084-7092.
116. Schubert M., Gautam D., Surjo D., Ueki K., Baudler S., Schubert D., Kondo T., Alber J., Galldiks N., Küstermann E., Arndt S., Jacobs A.H., Krone W., Kahn C.R., Brüning J.C. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 2004, 101:3100-3105.
117. Sengupta A., Kabat J., Novak M., Wu Q., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 1998, 357:299-309.
118. Sengupta A., Novak M., Grundke-Iqbal I., Iqbal K. Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett. 2006, 580:5925-5933.
119. Sergeant N., Bretteville A., Hamdane M., Caillet-Boudin M.L., Grognet P., Bombois S., Blum D., Delacourte A., Pasquier F., Vanmechelen E., Schraen-Maschke S., Buée L. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev. Proteomics 2008, 5:207-224.
120. Seubert P., Mawal-Dewan M., Barbour R., Jakes R., Goedert M., Johnson G.V., Litersky J.M., Schenk D., Lieberburg I., Trojanowski J.Q. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J. Biol. Chem. 1995, 270:18917-18922.
121. Shanavas A., Papasozomenos S.C. tau kinases in the rat heat shock model: possible implications for Alzheimer disease. Proc. Natl. Acad. Sci. USA 2000, 97:14139-14144.
122. Sironi J.J., Yen S.H., Gondal J.A., Wu Q., Grundke-Iqbal I., Iqbal K. Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Lett. 1998, 436:471-475.
123. Sluchanko N.N., Gusev N.B. Probable participation of 14-3-3 in tau protein oligomerization and aggregation. J. Alzheimers Dis. 2011, 27:467-476.
124. Sluchanko N.N., Seit-Nebi A.S., Gusev N.B. Phosphorylation of more than one site is required for tight interaction of human tau protein with 14-3-3zeta. FEBS Lett. 2009, 583:2739-2742.
125. Sobue K., Agarwal-Mawal A., Li W., Sun W., Miura Y., Paudel H.K. Interaction of neuronal Cdc2-like protein kinase with microtubule-associated protein tau. J. Biol. Chem. 2000, 275:16673-16680.
126. Songyang Z., Lu K.P., Kwon Y.T., Tsai L.H., Filhol O., Cochet C., Brickey D.A., Soderling T.R., Bartleson C., Graves D.J. A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol. Cell Biol. 1996, 16:6486.
127. Sontag E., Nunbhakdi-Craig V., Bloom G.S., Mumby M.C. A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle. J. Cell Biol. 1995, 128:1131-1144.
128. Sontag E., Nunbhakdi-Craig V., Lee G., Bloom G.S., Mumby M.C. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 1996, 17:1201-1207.
129. Sontag E., Nunbhakdi-Craig V., Lee G., Brandt R., Kamibayashi C., Kuret J., White C.L., Mumby M.C., Bloom G.S. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J. Biol. Chem. 1999, 274:25490-25498.
130. Sotelo-Silveira J.R., Calliari A., Kun A., Koenig E., Sotelo J.R. RNA trafficking in axons. Traffic 2006, 7:508-515.
131. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 1998, 95:6469-6473.
132. Spillantini M.G., Tolnay M., Love S., Goedert M. Microtubule-associated protein tau, heparan sulphate and alpha-synuclein in several neurodegenerative diseases with dementia. Acta Neuropathol. 1999, 97:585-594.
133. Stewart R., Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet. Med. 1999, 16:93-112.
134. Su S.C., Tsai L.H. Cyclin-dependent kinases in brain development and disease. Annu. Rev. Cell Dev. Biol. 2011, 27:465-491.
135. Sun W., Qureshi H.Y., Cafferty P.W., Sobue K., Agarwal-Mawal A., Neufield K.D., Paudel H.K. Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules. J. Biol. Chem. 2002, 277:11933-11940.
136. Takahashi K., Tanase-Nicola S., ten Wolde P.R. Spatio-temporal correlations can drastically change the response of a MAPK pathway. Proc. Natl. Acad. Sci. USA 2010, 107:2473-2478.
137. Taniguchi S., Fujita Y., Hayashi S., Kakita A., Takahashi H., Murayama S., Saido T.C., Hisanaga S., Iwatsubo T., Hasegawa M. Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett. 2001, 489:46-50.
138. Thies E., Mandelkow E. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J. Neurosci. 2007, 27:2896-2907.
139. Tokimasa M., Minoura K., Hiraoka S., Tomoo K., Sumida M., Taniguchi T., Ishida T. Importance of local structures of second and third repeat fragments of microtubule-binding domain for tau filament formation. FEBS Lett. 2005, 579:3481-3486.
140. Umahara T., Uchihara T., Tsuchiya K., Nakamura A., Ikeda K., Iwamoto T., Takasaki M. Immunolocalization of 14-3-3 isoforms in brains with Pick body disease. Neurosci. Lett. 2004, 371:215-219.
141. Wada Y., Ishiguro K., Itoh T.J., Uchida T., Hotani H., Saito T., Kishimoto T., Hisanaga S. Microtubule-stimulated phosphorylation of tau at Ser202 and Thr205 by cdk5 decreases its microtubule nucleation activity. J. Biochem. (Tokyo) 1998, 124:738-746.
142. Wang Y.P., Biernat J., Pickhardt M., Mandelkow E., Mandelkow E.-M. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc. Natl. Acad. Sci. USA 2007, 104:10252-10257.
143. Watanabe A., Hasegawa M., Suzuki M., Takio K., Morishima-Kawashima M., Titani K., Arai T., Kosik K.S., Ihara Y. In vivo phosphorylation sites in fetal and adult rat tau. J. Biol. Chem. 1993, 268:25712.
144. Wu D., Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem. Sci. 2010, 35:161-168.
145. Xie Z., Samuels B.A., Tsai L. Cyclin-dependent kinase 5 permits efficient cytoskeletal remodeling-a hypothesis on neuronal migration. Cereb. Cortex 2006, 16(Suppl. 1):i64-i68.
146. Yanagawa H., Chung S.H., Ogawa Y., Sato K., Shibata-Seki T., Masai J., Ishiguro K. Protein anatomy: C-tail region of human tau protein as a crucial structural element in Alzheimer's paired helical filament formation in vitro. Biochemistry 1998, 37:1979-1988.
147. Yano M., Nakamuta S., Wu X., Okumura Y., Kido H. A novel function of 14-3-3 protein: 14-3-3zeta is a heat-shock-related molecular chaperone that dissolves thermal-aggregated proteins. Mol. Biol. Cell 2006, 17:4769-4779.
148. Yu D.Y., Tong L., Song G.J., Lin W.L., Zhang L.Q., Bai W., Gong H., Yin Y.X., Wei Q. Tau binds both subunits of calcineurin, and binding is impaired by calmodulin. Biochim. Biophys. Acta 2008, 1783:2255-2261.
149. Yuan Z., Agarwal-Mawal A., Paudel H.K. 14-3-3 binds to and mediates phosphorylation of microtubule-associated tau protein by Ser9-phosphorylated glycogen synthase kinase 3beta in the brain. J. Biol. Chem. 2004, 279:26105-26114.
150. Zheng-Fischhöfer Q., Biernat J., Mandelkow E.M., Illenberger S., Godemann R., Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur. J. Biochem. 1998, 252:542-552.